Research location
Yvoir
Belgium
Advertisement
Research activity in Yvoir
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 122 trials and 123 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Yvoir
122 linked trials · page 1 of 3A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)NCT07222332 · 2026-02-05 · 1 site observation
RECRUITING
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary HypertensionNCT07359599 · 2026-01-27 · 1 site observation
RECRUITING
Effect of IMT in Patients After Acute Exacerbations of COPDNCT07213128 · 2026-01-06 · 1 site observation
RECRUITING
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation
RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation
RECRUITING
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037 · 2025-10-31 · 1 site observation
RECRUITING
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16 · 1 site observation
RECRUITING
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21 · 1 site observation
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
The CATALINA StudyNCT05008081 · 2022-10-25 · 1 site observation
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCNCT06219317 · 2025-01-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Snapshot Study on Patients With Heart FailureNCT06469814 · 2024-09-27 · 1 site observation
ENROLLING_BY_INVITATION
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study for Observing Severe Asthma in Patients Treated With TezepelumabNCT05677139 · 2022-12-13 · 1 site observation
COMPLETED
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerNCT05620134 · 2022-10-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05037929 · 2021-10-05 · 1 site observation
COMPLETED
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisNCT04871919 · 2021-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)NCT04768296 · 2021-03-29 · 1 site observation
COMPLETED
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationNCT04685135 · 2021-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)NCT04656652 · 2020-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC PatientsNCT04127110 · 2020-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsNCT04538664 · 2020-10-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Immunotherapy in Lung Cancer: Treatment After IO Cessation.NCT04465942 · 2020-06-26 · 1 site observation
UNKNOWN
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From DepressionNCT04448431 · 2020-06-18 · 1 site observation
COMPLETED
The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMsNCT04414280 · 2020-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%NCT04139317 · 2020-01-22 · 1 site observation
TERMINATED
Factors of ILD in Newly Diagnosed Rheumatoid ArthritisNCT04002765 · 2019-11-01 · 1 site observation
UNKNOWN
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelNCT04133909 · 2019-10-30 · 1 site observation
COMPLETED
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412 · 2019-10-08 · 1 site observation
COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerNCT03906071 · 2019-07-15 · 1 site observation
TERMINATED
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)NCT03888066 · 2019-04-24 · 1 site observation
COMPLETED
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)NCT03840902 · 2019-04-16 · 1 site observation
TERMINATED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)NCT03631706 · 2018-10-01 · 1 site observation
COMPLETED
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumNCT03761901 · 2018-09-21 · 1 site observation
COMPLETED
A Study of REGN2810 and Ipilimumab in Patients With Lung CancerNCT03430063 · 2018-05-29 · 1 site observation
TERMINATED
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective RegistryNCT03368820 · 2017-12-04 · 1 site observation
UNKNOWN
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate CancerNCT02972060 · 2017-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.